The binding of ciamexone to globin: its demonstration and some accompanying effects in rats.
The 2-cyanaziridines Ciamexone and Azimexone in doses of 100 and 500 mg/kg lead to a reversible dose-dependent formation of thermolabile hemoglobin and Heinz bodies, a lowered erythrocyte count, and splenomegaly. According to our investigations these effects may have been caused by a covalent binding of the 2-cyanaziridines or their metabolites to globin in the erythrocytes. This binding was shown by gel electrophoresis using 14C-labeled Ciamexone. The change of the globin had no influence on the oxygen affinity of the hemoglobin.
D019794:2,3-Diphosphoglycerate; D000276:Adjuvants, Immunologic / Q000378:metabolism*; D000818:Animals; D001388:Aziridines / Q000378:metabolism*; D001389:Azirines / Q000378:metabolism*; D004163:Diphosphoglyceric Acids / Q000097:blood; D006366:Heinz Bodies / Q000378:metabolism; D006454:Hemoglobins / Q000032:analysis / Q000378:metabolism*; D008297:Male; D010100:Oxygen / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains
D000276:Adjuvants, Immunologic; D001388:Aziridines; D001389:Azirines; D004163:Diphosphoglyceric Acids; D006454:Hemoglobins; D019794:2,3-Diphosphoglycerate; C035520:ciamexon; C016866:azimexon; D010100:Oxygen